Silicon Matrix Calcium Phosphate as a Bone Substitute: Early Clinical and Radiological Results in a Prospective Study With 12-Month Follow-up

The clinical results from this study of silicon matrix calcium phosphate are consistent with previous in vitro studies indicating that this material stimulates formation of a bioactive layer and provides an effective bone graft material for lumbar fusion applications. In comparison with previous studies involving rhBMP-2, silicon matrix calcium phosphate provided a lower fusion rate at 3- and 6-month follow-up points, but after 12 months, the fusion rate was similar, with no statistical differences and lower overall costs. No clinically relevant adverse events were associated with either the cage or graft material. With increasing evidence of high rates of enhanced fusion development in this spinal application, additional research is encouraged, including longer periods of follow-up, to further confirm the efficacy of silicon matrix calcium phosphate as a safe and effective bone graft substitute.